Biotechnology Assets (BST.MC) Stock Price

Biotechnology Assets Price

BME·CLOSED
0.20EUR-0.0030 (-1.48 %)
Market closed

Over the last 14 years Biotechnology Assets grew revenue by 22.9% annually, reaching 2.51 M EUR. Earnings per share have declined at 11.9% per year over the last 13 years. For Biotechnology Assets, the net margin of -116.0% is up versus -341.7% a few years ago. The stock trades about 10% above its 52-week low.

Biotechnology Assets stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Biotechnology Assets over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biotechnology Assets stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biotechnology Assets's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Biotechnology Assets Stock Price History
DateBiotechnology Assets Price
7/21/20260.20 EUR
7/20/20260.20 EUR
7/17/20260.20 EUR
7/16/20260.20 EUR
7/15/20260.20 EUR
7/14/20260.20 EUR
7/13/20260.20 EUR
7/10/20260.21 EUR
7/9/20260.21 EUR
7/8/20260.21 EUR
7/7/20260.21 EUR
7/6/20260.22 EUR
7/3/20260.23 EUR
7/2/20260.23 EUR
7/1/20260.23 EUR
6/30/20260.24 EUR
6/29/20260.23 EUR
6/26/20260.23 EUR
6/25/20260.24 EUR
6/24/20260.24 EUR
6/23/20260.24 EUR
6/22/20260.25 EUR
6/19/20260.24 EUR
6/18/20260.25 EUR
6/17/20260.25 EUR
6/16/20260.25 EUR
6/15/20260.25 EUR
6/12/20260.23 EUR
6/11/20260.25 EUR
6/10/20260.24 EUR
6/9/20260.25 EUR
6/8/20260.25 EUR
6/5/20260.25 EUR
6/4/20260.26 EUR
6/3/20260.25 EUR
6/2/20260.25 EUR
6/1/20260.25 EUR
5/29/20260.25 EUR
5/28/20260.26 EUR
5/27/20260.26 EUR
5/26/20260.27 EUR
5/25/20260.27 EUR
5/22/20260.27 EUR
5/21/20260.26 EUR
5/20/20260.25 EUR
5/19/20260.25 EUR
5/18/20260.23 EUR
5/15/20260.23 EUR
5/14/20260.23 EUR
5/13/20260.23 EUR
5/12/20260.23 EUR
5/11/20260.23 EUR
5/8/20260.25 EUR
5/7/20260.25 EUR
5/6/20260.25 EUR
5/5/20260.25 EUR
5/4/20260.26 EUR
4/30/20260.27 EUR
4/29/20260.28 EUR
4/28/20260.27 EUR
4/27/20260.25 EUR
4/24/20260.26 EUR
4/23/20260.26 EUR
4/22/20260.26 EUR
4/21/20260.25 EUR
4/20/20260.24 EUR
4/17/20260.24 EUR
4/16/20260.24 EUR
4/15/20260.24 EUR
4/14/20260.24 EUR
4/13/20260.24 EUR
4/10/20260.23 EUR
4/9/20260.23 EUR
4/8/20260.23 EUR
4/7/20260.23 EUR
4/2/20260.23 EUR
4/1/20260.23 EUR
3/31/20260.24 EUR
3/30/20260.24 EUR
3/27/20260.23 EUR
3/26/20260.24 EUR
3/25/20260.24 EUR
3/24/20260.23 EUR
3/23/20260.22 EUR
3/20/20260.22 EUR
3/19/20260.23 EUR
3/18/20260.24 EUR
3/17/20260.22 EUR
3/16/20260.24 EUR
3/13/20260.21 EUR
3/12/20260.21 EUR
3/11/20260.21 EUR
3/10/20260.21 EUR
3/9/20260.21 EUR
3/6/20260.20 EUR
3/5/20260.20 EUR
3/4/20260.20 EUR
3/3/20260.20 EUR
3/2/20260.21 EUR
2/27/20260.22 EUR
2/26/20260.22 EUR
2/25/20260.23 EUR
2/24/20260.25 EUR
2/23/20260.23 EUR
2/20/20260.19 EUR
2/19/20260.19 EUR
2/18/20260.19 EUR
2/17/20260.19 EUR
2/16/20260.19 EUR
2/13/20260.19 EUR
2/12/20260.19 EUR
2/11/20260.19 EUR
2/10/20260.20 EUR
2/9/20260.20 EUR
2/6/20260.19 EUR
2/5/20260.20 EUR
2/4/20260.20 EUR
2/3/20260.20 EUR
2/2/20260.22 EUR
1/30/20260.22 EUR
1/29/20260.23 EUR
1/28/20260.22 EUR
1/27/20260.21 EUR
1/26/20260.20 EUR
1/23/20260.20 EUR
1/22/20260.20 EUR
1/21/20260.19 EUR
1/20/20260.19 EUR
1/19/20260.18 EUR
1/16/20260.19 EUR
1/15/20260.19 EUR
1/14/20260.19 EUR
1/13/20260.19 EUR
1/12/20260.20 EUR
1/9/20260.20 EUR
1/8/20260.19 EUR
1/7/20260.18 EUR
1/6/20260.19 EUR
1/5/20260.20 EUR
1/2/20260.20 EUR
12/31/20250.20 EUR
12/30/20250.20 EUR
12/29/20250.22 EUR
12/24/20250.23 EUR
12/23/20250.23 EUR
12/22/20250.23 EUR
12/19/20250.23 EUR
12/18/20250.23 EUR
12/17/20250.24 EUR
12/16/20250.25 EUR
12/15/20250.25 EUR
12/12/20250.26 EUR
12/11/20250.26 EUR
12/10/20250.27 EUR
12/9/20250.28 EUR
12/8/20250.28 EUR
12/5/20250.28 EUR
12/4/20250.28 EUR
12/3/20250.29 EUR
12/2/20250.29 EUR
12/1/20250.31 EUR
11/28/20250.31 EUR
11/27/20250.31 EUR
11/26/20250.32 EUR
11/25/20250.31 EUR
11/24/20250.30 EUR
11/21/20250.30 EUR
11/20/20250.30 EUR
11/19/20250.30 EUR
11/18/20250.31 EUR
11/17/20250.30 EUR
11/14/20250.31 EUR
11/13/20250.32 EUR
11/12/20250.31 EUR
11/11/20250.31 EUR
11/10/20250.31 EUR
11/7/20250.33 EUR
11/6/20250.33 EUR
11/5/20250.34 EUR
11/4/20250.32 EUR
11/3/20250.33 EUR
10/31/20250.34 EUR
10/30/20250.35 EUR
10/29/20250.35 EUR
10/28/20250.35 EUR
10/27/20250.35 EUR
10/24/20250.36 EUR
10/23/20250.36 EUR
10/22/20250.36 EUR
10/21/20250.37 EUR
10/20/20250.37 EUR
10/17/20250.37 EUR
10/16/20250.37 EUR
10/15/20250.37 EUR
10/14/20250.38 EUR
10/13/20250.39 EUR
10/10/20250.40 EUR
10/9/20250.40 EUR
10/8/20250.40 EUR
10/7/20250.41 EUR
10/6/20250.39 EUR
10/3/20250.39 EUR
10/2/20250.39 EUR
10/1/20250.39 EUR
9/30/20250.38 EUR
9/29/20250.38 EUR
9/26/20250.37 EUR
9/25/20250.37 EUR
9/24/20250.36 EUR
9/23/20250.37 EUR
9/22/20250.38 EUR
9/19/20250.38 EUR
9/18/20250.38 EUR
9/17/20250.38 EUR
9/16/20250.38 EUR
9/15/20250.39 EUR
9/12/20250.39 EUR
9/11/20250.39 EUR
9/10/20250.38 EUR
9/9/20250.38 EUR
9/8/20250.38 EUR
9/5/20250.40 EUR
9/4/20250.41 EUR
9/3/20250.41 EUR
9/2/20250.43 EUR
9/1/20250.45 EUR
8/29/20250.46 EUR
8/28/20250.38 EUR
8/27/20250.39 EUR
8/26/20250.40 EUR
8/25/20250.39 EUR
8/22/20250.39 EUR
8/21/20250.38 EUR
8/20/20250.39 EUR
8/19/20250.36 EUR
8/18/20250.36 EUR
8/15/20250.36 EUR
8/14/20250.37 EUR
8/13/20250.36 EUR
8/12/20250.36 EUR
8/11/20250.36 EUR
8/8/20250.36 EUR
8/7/20250.36 EUR
8/6/20250.35 EUR
8/5/20250.34 EUR
8/4/20250.35 EUR
8/1/20250.35 EUR
7/31/20250.36 EUR
7/30/20250.36 EUR
7/29/20250.36 EUR
7/28/20250.37 EUR
7/25/20250.36 EUR
7/24/20250.38 EUR
7/23/20250.37 EUR
Access this data via the Eulerpool API
Get Free API Key

Biotechnology Assets Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
2.39 M EUR
-260,000.00 EUR
-70,000.00 EUR
Jan 1, 2018
23.32 M EUR
-14.41 M EUR
-16.98 M EUR
Jan 1, 2019
2.13 M EUR
-1.88 M EUR
-10.08 M EUR
Jan 1, 2020
2.52 M EUR
-570,000.00 EUR
-8.61 M EUR
Jan 1, 2021
3.09 M EUR
-1.42 M EUR
-3.01 M EUR
Jan 1, 2022
2.61 M EUR
-1.09 M EUR
-1.94 M EUR
Jan 1, 2023
3.60 M EUR
3.35 M EUR
1.57 M EUR
Jan 1, 2024
2.51 M EUR
-2.00 M EUR
-2.92 M EUR

Biotechnology Assets Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 22, 2026, 9:57 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201020112012201320142015201620172018201920202021202220232024
––––1.001.001.002.0023.002.002.003.002.003.002.00
–––––––100.001,050.00-91.30–50.00-33.3350.00-33.33
––––200.00100.00200.00150.004.3550.00100.0033.3350.0066.6750.00
1.001.001.001.002.001.002.003.001.001.002.001.001.002.001.00
––––––-1.00–-14.00-1.00–-1.00-1.003.00-2.00
––––––-100.00–-60.87-50.00–-33.33-50.00100.00-100.00
––––1.00–-1.00–-16.00-10.00-8.00-3.00-1.001.00-2.00
–––––––––-37.50-20.00-62.50-66.67-200.00-300.00
3.863.864.084.214.604.635.095.0939.1839.1739.1945.6154.2057.7357.75
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Biotechnology Assets generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biotechnology Assets retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biotechnology Assets's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Biotechnology Assets has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biotechnology Assets's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Biotechnology Assets stock margins

The Biotechnology Assets margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biotechnology Assets. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biotechnology Assets.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
137.24 %
-10.88 %
-2.93 %
Jan 1, 2018
1.42 %
-61.79 %
-72.81 %
Jan 1, 2019
77.00 %
-88.26 %
-473.24 %
Jan 1, 2020
83.73 %
-22.62 %
-341.67 %
Jan 1, 2021
48.22 %
-45.95 %
-97.41 %
Jan 1, 2022
67.05 %
-41.76 %
-74.33 %
Jan 1, 2023
68.45 %
92.90 %
43.70 %
Jan 1, 2024
76.12 %
-79.64 %
-116.01 %

Biotechnology Assets Stock Revenue, EBIT, Earnings per Share

The Biotechnology Assets earnings per share therefore indicates how much revenue Biotechnology Assets has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
0.47 EUR
-0.05 EUR
-0.01 EUR
Jan 1, 2018
0.60 EUR
-0.37 EUR
-0.43 EUR
Jan 1, 2019
0.05 EUR
-0.05 EUR
-0.26 EUR
Jan 1, 2020
0.06 EUR
-0.01 EUR
-0.22 EUR
Jan 1, 2021
0.07 EUR
-0.03 EUR
-0.07 EUR
Jan 1, 2022
0.05 EUR
-0.02 EUR
-0.04 EUR
Jan 1, 2023
0.06 EUR
0.06 EUR
0.03 EUR
Jan 1, 2024
0.04 EUR
-0.03 EUR
-0.05 EUR

Biotechnology Assets business model & stock analysis

ADL Bionatur Solutions SA is a Swiss company specializing in the development and production of natural ingredients for the food, cosmetics, and pharmaceutical industries. The company was founded in 2000 and has since had an impressive success story. ADL Bionatur Solutions SA's business model is based on the use of plants and microorganisms to extract high-quality natural active ingredients. The company employs environmentally friendly methods and sustainable production practices that meet the needs of society and nature alike. One of ADL Bionatur Solutions SA's main sectors is the production of natural flavors and colorants for the food industry. Depending on customer preferences, color pigments are extracted from fruits, vegetables, or other plants to color food products with natural ingredients. Natural flavors are also isolated using plant extracts and other natural sources. These products are particularly sought after because they are not only healthier than synthetic alternatives but also provide consumers with a better feeling. Another significant sector of ADL Bionatur Solutions SA is the development of cosmetics based on natural ingredients. For example, extracts from algae, flowers, or herbs are used to create skincare products that are gentle on the skin while still being highly effective. Products targeting signs of aging or acne are also based on natural ingredients from ADL Bionatur Solutions SA. In addition to these two main sectors, ADL Bionatur Solutions SA also offers products for the pharmaceutical industry. The company focuses on developing active ingredients based on natural substances that can be used to treat various diseases. Sustainability is also a key focus here, as naturally derived active ingredients are not only healthier but also have a higher biological availability. In addition to these main sectors, ADL Bionatur Solutions SA provides consulting services to customers. This includes the development of tailored natural solutions and support for product certification according to the highest international standards. Overall, in recent years, ADL Bionatur Solutions SA has become one of the world's leading companies in the field of natural ingredients. With a wide portfolio of products and services and a strong focus on sustainability and environmental compatibility, the company is well-positioned to benefit from the ongoing trend towards natural and healthier products.

Biotechnology Assets SWOT Analysis

Strengths

ADL Bionatur Solutions SA possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company has a strong portfolio of innovative and high-quality bio-based solutions, which sets it apart from its competitors. Its expertise in biotechnology and sustainable solutions enables it to develop and offer unique products that meet the evolving needs of customers.

Secondly, ADL Bionatur Solutions SA has a robust research and development team, dedicated to continuous improvement and new product development. This allows the company to stay at the forefront of technological advancements in the industry and maintain its position as an innovation leader.

Additionally, the company benefits from strategic partnerships with key players in the bio-based solutions market. These alliances provide access to new markets, distribution channels, and resources, enhancing ADL Bionatur Solutions SA's market reach and brand recognition.

Weaknesses

Despite its strengths, ADL Bionatur Solutions SA also faces a few weaknesses that could hinder its growth and competitiveness. One of these weaknesses is the company's relatively small size compared to some of its competitors. This may limit its capacity to invest in large-scale production and distribution facilities, potentially impacting its ability to efficiently meet growing market demand.

Another weakness lies in the limited geographic presence of ADL Bionatur Solutions SA. The company currently operates primarily in specific regions, which makes it more susceptible to fluctuations in local market conditions and economic challenges.

Opportunities

ADL Bionatur Solutions SA operates in a sector with significant growth potential and numerous opportunities. One of these opportunities is the increasing global demand for sustainable and eco-friendly solutions. As consumers and businesses become more environmentally-conscious, there is a growing market for ADL Bionatur Solutions SA's bio-based products.

Additionally, the expanding preference for natural and organic ingredients in various industries, such as cosmetics, agriculture, and food, presents opportunities for ADL Bionatur Solutions SA to further diversify and expand its product offerings.

Threats

Despite the favorable market conditions, ADL Bionatur Solutions SA faces certain threats that could impact its operations and profitability. One significant threat is the presence of intense competition within the bio-based solutions industry. Other companies, including multinational corporations, may offer similar products or enter the market with competitive innovations, posing a challenge to ADL Bionatur Solutions SA's market share.

Furthermore, regulatory changes and policies related to the use of bio-based products and chemicals may pose compliance challenges and impact the demand for ADL Bionatur Solutions SA's offerings. The company must closely monitor and adapt to changing regulations to avoid any negative consequences.

Biotechnology Assets Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Biotechnology Assets historical P/E ratio, EBIT multiple, and P/S ratio

Biotechnology Assets annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Biotechnology Assets shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
5.09 M Stocks
Jan 1, 2018
39.18 M Stocks
Jan 1, 2019
39.17 M Stocks
Jan 1, 2020
39.19 M Stocks
Jan 1, 2021
45.61 M Stocks
Jan 1, 2022
54.20 M Stocks
Jan 1, 2023
57.73 M Stocks
Jan 1, 2024
57.75 M Stocks
Price targets and forecasts for Biotechnology Assets are not yet available.

Biotechnology Assets shareholder structure

% Name
38.19912%
BTC Uno S.a.r.l.
BTC Uno S.a.r.l.
7.74407%
BTC Diez, S.à.R.L
BTC Diez, S.à.R.L
0.09676%
GVC Gaesco Gestión SGIIC S.A.
GVC Gaesco Gestión SGIIC S.A.

Biotechnology Assets Executives and Management Board

VV

Mr. Victor Manuel Infante Vinolo

Chairman of the Board · since 2022

JD

Mr. John Dixon

Director

JM

Mr. Jeronimo Herrero Manso

Director

AG

Mr. Andres Seco Garcia

Director

Frequently asked questions about Biotechnology Assets

The business model of ADL Bionatur Solutions SA is focused on developing and commercializing natural ingredients and functional solutions for various industries. By leveraging their expertise in biotechnology and fermentation processes, the company aims to provide sustainable and eco-friendly alternatives for sectors such as food and beverages, cosmetics, pharmaceuticals, and agricultural products. ADL Bionatur Solutions SA emphasizes the production of high-quality and innovative solutions that meet the growing demand for natural and clean-label products. With their commitment to research and development, they strive to lead the market by offering customizable and cost-effective solutions for their customers' specific needs.

All fundamentals and in-depth analysis of Biotechnology Assets

Our stock analysis for Biotechnology Assets stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotechnology Assets. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Biotechnology Assets Stock
Biotechnology Assets Revenue→
Biotechnology Assets Stock
Biotechnology Assets Net Income→
Biotechnology Assets Stock
Biotechnology Assets P/E→
Biotechnology Assets Stock
Biotechnology Assets P/S→
Biotechnology Assets Stock
Biotechnology Assets EBIT→
Biotechnology Assets Stock
Biotechnology Assets Dividend→
Biotechnology Assets Stock
Biotechnology Assets Directors Dealings→
Biotechnology Assets Stock
Biotechnology Assets Stocks→
Biotechnology Assets Stock
Biotechnology Assets Market capitalization→
Biotechnology Assets Stock
Biotechnology Assets Debt→
Biotechnology Assets Stock
Biotechnology Assets Liabilities→
Biotechnology Assets Stock
Biotechnology Assets Equity→
Biotechnology Assets Stock
Biotechnology Assets AAQS→
Biotechnology Assets Stock
Biotechnology Assets Employees→
Biotechnology Assets Stock
Biotechnology Assets ROE→
Biotechnology Assets Stock
Biotechnology Assets ROA→
Biotechnology Assets Stock
Biotechnology Assets ROCE→
Biotechnology Assets Stock
Biotechnology Assets News→
Biotechnology Assets Stock
Biotechnology Assets Analyst Price Targets→

Health Stocks

BiotequeBioteBiotonBiosynexBioToxTech CoBioSyentBiotronBiostem TechnologiesBioventixBiostaxBioventusBiostar PharmaceuticalsAll Stocks A–Z →